Canopy Growth screens cheap on a price-to-sales basis but carries a quality score well below the engine's floor, a confirmed technical downtrend after a roughly 58% drawdown, and a string of severe earnings misses accompanied by bearish insider selling, so any recovery case rests on early technical signs of stabilization rather than confirmed fundamentals.
Thesis pillars
- Cheap Price To Sales→Stable
- Quality Below Floor→Stable
- Confirmed Downtrend Deep Drawdown→Stable
- +1 more pillar — see the Why tab for full reasoning
Canopy Growth Corporation (CGC) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $0.96: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Elevated put/call ratio: 14.00; Below-average business quality; Below long-term trend.
Canopy Growth Corporation is a Canada-based cannabis company producing and selling adult-use and medical cannabis products under brands including Tweed, DOJA, and Spectrum Therapeutics, plus vaporizer devices through its Storz & Bickel subsidiary, with operations in Canada,... Read more
Sell if holding. Engine safety override at $0.96: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Elevated put/call ratio: 14.00; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 51. Score 5.2/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and SEC filing concern. Suitability: speculative.
About Canopy Growth Corporation
About Canopy Growth Corporation
Canopy Growth produces and sells cannabis flower, pre-rolls, edibles, vapes, and extracts under brands including Tweed, DOJA, and Spectrum Therapeutics across Canada, Germany, Poland, and Australia, alongside Storz & Bickel vaporizer devices exported to more than 100 countries. The company holds a non-controlling equity stake in Canopy USA for indirect U.S. cannabis exposure pending Nasdaq/NYSE listing rule changes. In May 2026, Canopy's Audit Committee concluded its fiscal 2024 and 2025 financial statements should no longer be relied upon due to warrant-accounting errors.
Canopy earns revenue through direct-to-patient medical sales via its Spectrum Therapeutics and Abba Medix online platforms and its Apollo, Canada House, and Abba Medix clinic network, and through adult-use wholesale supply agreements with every Canadian province and territory's retail distribution system. Cultivation is concentrated in three Canadian facilities — a hybrid greenhouse in Kincardine, Ontario (EU-GMP certified for medical exports to Europe and Australia) and indoor facilities in Pointe Claire and Louiseville, Quebec — while vapes, edibles, and extracts are largely sourced through third-party manufacturers. The company completed its acquisition of MTL Cannabis in fiscal 2026 to add cultivation genetics and talent, and separately entered a new loan and guaranty agreement on January 8, 2026. Beyond the financial restatement, Canopy disclosed a $47.5 million impairment of Storz & Bickel goodwill in fiscal 2026 and remains subject to an ongoing regulatory investigation tied to its prior self-reported BioSteel accounting review.
Show full overview
Canopy's most consequential near-term risk is not cannabis-market competition but its own accounting infrastructure: the company restated audited financial statements for fiscal 2024 and 2025, plus eight quarters of unaudited interim statements, after concluding its accounting for U.S.-dollar-denominated share-settled warrants contained non-cash technical errors, and management determined that internal control over financial reporting was not effective as of March 31, 2026. With putative shareholder class actions a disclosed possibility and a separate regulatory investigation still open following the company's self-reported BioSteel accounting review, Canopy's ability to raise capital or maintain its Nasdaq and TSX listings depends on successfully remediating these control weaknesses rather than on any single product launch or market expansion.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Canopy Growth Corporation's most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-05-15Item 4.02HIGHCanopy Growth's Audit Committee concluded on May 15, 2026 that its previously issued FY2024 and FY2025 audited financial statements, and unaudited quarterly statements from September 2023 through December 2025, should no longer be relied upon due to non-cash technical accounting errors involving share-settled warrants with U.S.-dollar exercise prices first issued in fiscal 2024.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -92.4%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $0.96: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Elevated put/call ratio: 14.00; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 51. Prior stop was $0.90. Score 5.2/10, moderate confidence.
Take-profit target: $1.04 (+7.8% upside). Prior stop was $0.90. Stop-loss: $0.90.
Quality below floor (2.5 < 4.0).
Canopy Growth Corporation trades at a P/E of N/A (forward -8.0). TrendMatrix value score: 9.3/10. Verdict: Sell.
12 analysts cover CGC with a consensus score of 3.8/5. Average price target: $1.
What does Canopy Growth Corporation do?Canopy Growth Corporation is a Canada-based cannabis company producing and selling adult-use and medical cannabis...
Canopy Growth Corporation is a Canada-based cannabis company producing and selling adult-use and medical cannabis products under brands including Tweed, DOJA, and Spectrum Therapeutics, plus vaporizer devices through its Storz & Bickel subsidiary, with operations in Canada, Europe, and Australia and a non-controlling equity stake in Canopy USA for indirect U.S. exposure. In May 2026, the company's Audit Committee determined its fiscal 2024 and 2025 financial statements should no longer be relied upon due to accounting errors in U.S.-dollar warrants, triggering a restatement, a disclosed materi